tRNA therapeutics burst onto startup scene

tRNA therapeutics burst onto startup scene

Companies advance tRNA therapeutics to overcome mutant stoppages in protein synthesis shared by thousands of genetic diseases and cancers.

But Alltrna is hardly alone in its pursuit of tRNA-based therapeutics. ReCode Therapeutics, Shape Therapeutics and Tevard Biosciences all came before it; and the field continues to expand with the arrival of hC Bioscience, a startup that emerged from stealth mode in late February with $24 million and a plan to fight cancer and rare diseases with tRNA.

This is a preview of subscription content

Access options

Subscribe to Journal

Get full journal access for 1 year

100,85 €

only 8,40 € per issue

Tax calculation will be finalised during checkout.

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Author information

Affiliations

  1. Somerville, MA, USA

    Elie Dolgin

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. tRNA therapeutics burst onto startup scene.
Nat Biotechnol (2022). https://doi.org/10.1038/s41587-022-01252-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41587-022-01252-y

Read More

[an error occurred while processing the directive]